StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a research note published on Sunday morning. The firm issued a sell rating on the stock.

Separately, Needham & Company LLC reaffirmed a buy rating and issued a $4.25 target price on shares of OncoCyte in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of Hold and a consensus price target of $4.06.

OncoCyte Stock Down 1.3 %

OncoCyte stock opened at $3.11 on Friday. The business has a 50 day moving average price of $3.13 and a two-hundred day moving average price of $2.93. OncoCyte has a 12 month low of $2.08 and a 12 month high of $4.34.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%. The business had revenue of $0.10 million during the quarter.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.